HOME >> BIOLOGY >> NEWS
Other highlights in the May 19 JNCI

Two Studies Examine Safe Three Agent Combination Therapy for HER2-Positive Advanced Breast Cancer

Combinations of docetaxel, cisplatin or carboplatin, and the monoclonal antibody trastuzumab are feasible for the treatment of patients with HER2-positive advanced breast cancer in which tumor response rates are high, according to two new studies.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in the tumors of 20-30% of breast cancer patients and is associated with an increased risk of relapse and death in patients with early-stage breast cancer. In earlier clinical trials, adding trastuzumab, which blocks the effects of HER2, to standard chemotherapy increased both the response rate of patients and survival, but an unacceptable number of patients experienced cardiac dysfunction, including congestive heart disease.

In the first of two studies designed to find safer chemotherapy combinations that include trastuzumab, Mark D. Pegram, M.D., of the University of California, Los Angeles, and colleagues characterized the interactions between trastuzumab and nine chemotherapy drugs commonly used in treating breast cancer in four cell lines that overexpress HER2. They found synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine, which indicated that these were reasonable combinations to test in human clinical trials.

In the second study, a second group of researchers also led by Pegram, conducted two phase II clinical trials to evaluate the combination of docetaxel and trastuzumab with either of two platinum salts, cisplatin or carboplatin. In each trial, the combinations were tested on 62 women with advanced breast cancer that overexpressed HER2. Both combinations had a similar toxicity to docetaxel plus platinum salts alone, and there was a low incidence of cardiac dysfunction. In addition, overall response rates were higher. The combinations are now being tested
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
18-May-2004


Page: 1 2 3 4

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... ... August 14, 2019 , ... Gateway Genomics , a leading ... inclusion in the 38th annual Inc. 500|5000 list of fastest growing private ... companies must have been founded and generating revenue by March 31, 2015. Ranking in ...
(Date:8/14/2019)... ... ... Julie Reck of Veterinary Medical Center of Fort Mill has recently begun providing ... her own geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis in his ... body was weak, and he struggled to play fetch and other games with his family. ...
(Date:8/6/2019)... ... August 06, 2019 , ... A study released today in ... far-reaching implications for personalized medicine, especially when seeking treatments for children with heart ... which stem cell donors and manipulation methods might yield the best therapies for ...
Breaking Biology News(10 mins):
(Date:9/11/2019)... ... 2019 , ... An upcoming episode of Advancements with Ted ... sequencing analysis. Check your local listings for more information. , Advancements will go ... and will explore its revolutionary pathogenic DNA analysis technology, which predicts in real-time, ...
(Date:9/8/2019)... , ... September 05, 2019 , ... ... Blaine Fitzgerald, former Vice President of Finance for Shopify, has been named Chief ... and healthcare venture capitalist Joel Finlayson as strategic advisors. Additionally, Spartan has hired ...
(Date:8/29/2019)... ... August 28, 2019 , ... ... Danisco® ingredient solutions to attendees at the International Baking Industry Expo, September 8 ... challenges from optimizing production efficiency to cost and waste reduction and from maintaining ...
(Date:8/25/2019)... ... 2019 , ... Authors Gopal Nayak and Mahendra Kumar Trivedi ... “Impact of Biofield Treatment on Growth and Anatomical Characteristics of Pogostemon cablin (Benth.)" ... book garnered No. 1 status on Amazon in several categories including: Mind-Body Medicine, ...
Breaking Biology Technology:
Cached News: